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Purpose: Low-dose fractionated radiation therapy (LDFRT) induces effective cell killing through
hyperradiation sensitivity and potentiates effects of chemotherapy. We report our second investi-
gation of LDFRT as a potentiator of the chemotherapeutic effect of induction carboplatin and
paclitaxel in locally advanced squamous cell cancer of the head and neck (SCCHN).
Experimental design: Twocyclesof induction therapyweregiven every21days:paclitaxel (75mg/m2)
on days 1, 8, and 15; carboplatin (area under the curve 6) day 1; and LDFRT 50 cGy fractions (2 each
on days 1, 2, 8, and 15). Objectives included primary site complete response rate; secondary included
overall survival, progression-free survival (PFS), disease-speciﬁc survival, and toxicity.This work was presented in abstract and poster form at the 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO), Miami,
FL, October 2-4, 2011.
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Advances in Radiation Oncology: OctobereDecember 2016 Low-dose radiation induction in SCCH 253Results: A total of 24 evaluable patients were enrolled. Primary sites included oropharynx (62.5%),
larynx (20.8%), oral cavity (8.3%), and hypopharynx (8.3%). Grade 3/4 toxicities included neutropenia
(20%), leukopenia (32%), dehydration/hypotension (8%), anemia (4%), infection (4%), pulmonar-
y/allergic rhinitis (4%), and diarrhea (4%). Primary site response rate was 23/24 (95.8%): 15/24
(62.5%) complete response, 8/24 (33.3%) partial response, and 1/24 (4.2%) stable disease. With
median follow-up of 7.75 years, 9-year rates for overall survival were 49.4% (95% conﬁdence
interval [CI], 30.5-79.9), PFS was 72.2% (CI, 55.3-94.3), and disease-speciﬁc survival was 65.4%
(44.3-96.4).
Conclusion: Chemopotentiating LDFRT combined with paclitaxel and carboplatin is effective in
SCCHN and provided an excellent median overall survival of 107.2 months, with median PFS not yet
reached in this locally advanced SCCHN cohort. This compares favorably to prior investigations and
caused fewer grade 3 and 4 toxicities than more intensive, 3-drug induction regimens. This trial
demonstrates the innovative use of LDFRT as a potentiator of chemotherapy.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Locally advanced squamous cell carcinoma of the head
and neck (SCCHN) remains a challenge to oncologists,
with 12,290 deaths estimated in 2015 alone, despite
aggressive multidisciplinary care.1 Human papillomavirus
(HPV) status has become a deﬁning prognostic marker for
survival in this disease, effectively delineating prognostic
groups both in oropharyngeal sites2-7 and others. Despite
advances in our understanding of the molecular mecha-
nisms of this disease, survival has improved only 5% in
the past 20 years.8 Although concurrent chemotherapy
and radiation remains the standard of care in locally
advanced disease of the oropharynx, hypopharynx, and
larynx, the 5-year overall survival (OS) of varies from
10% to 82% depending on site, nodal involvement, race,
HPV status, and comorbidities.9-11
Induction chemotherapy followed by concurrent che-
moradiation therapy is 1 of several options available to
patients in the treatment of locally advanced SCCHN,12,13
but induction therapy carries the risk of acute toxicity,
including neutropenia, fatigue, mucositis, and infec-
tion.14-21 The combination of docetaxel, cisplatin, and
ﬂuorouracil has been the most widely used because of
complementary mechanisms of action, improved radiation
sensitization, and excellent response rates, albeit with
increased toxicity22; however, the acceptance of induction
therapy has been slow because of the perceived toxicity of
induction, the success of combined modality therapy, and
improved efﬁcacy of other agents such as epidermal
growth factor receptorebased immunotherapies, and in-
duction therapy remains controversial.13,16,23,24
Induction therapy allows for rapid assessment of
sensitivity to the regimen given, providing an excellent
assessment of efﬁcacy. We designed a novel induction
regimen to study the synergy of low-dose fractionated
radiation (LDFRT) combined with platinum-based
doublet therapy. In this setting, LDFRT served as thethird therapeutic agent in the induction treatment and was
intended to provide an agent regimen that would remain
less toxic than triplet chemotherapy.25,26 Joiner and col-
leagues27 recognized the therapeutic potential of low-dose
radiation more than 20 years ago when they demonstrated
an initial phase of hyperradiosensitivity (HRS) using
doses from 0 to 80 cGy. The HRS observed with low-
dose radiation is a unique radiobiologic phenomenon,28
and was reported to enhance chemotherapy-induced the
cell death by overcoming the antiapoptotic effects of bcl-2
and nuclear factor kappa-B29 when delivered in 4 very
low doses (termed ultrafractionation) in vitro.29
Preclinical data indicated optimal HRS at doses of 50
to 80 cGy given 4 times over 24 hours and led to the
design and initial success of a clinical trial of paclitaxel,
carboplatin, and LDFRT induction therapy in locally
advanced SCCHN, without signiﬁcant change in the
toxicity proﬁle over chemotherapy alone.30 Long-term
outcomes of this ﬁrst trial have been reported26 and led
to a second trial examining a different schedule of
LDFRT and chemotherapy with the primary endpoint of
improved primary site complete response (CR) rate and
secondary survival endpoints of nodal response, overall
response rate (RR), OS, progression-free survival (PFS),
and toxicity. Initial efﬁcacy of this regimen has previously
been presented in abstract form, and we report the mature
phase 2 results of this treatment paradigm from our sec-
ond clinical trial of chemotherapy and LDFRT as induc-
tion in SCCHN.Methods and materials
Patient characteristics and eligibility criteria
Subjects were enrolled from December 19, 2002, until
September 20, 2004. All patients signed informed consent
approved by the University institutional review board.
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stage III or IV SCCHN (excluding distant metastatic
disease) within 2 months of diagnosis. All patients un-
derwent computed tomography (CT) or magnetic reso-
nance imaging scan of the involved area of the head and
neck, chest x-ray or chest CT scan, and direct laryngos-
copy with biopsy of the affected area. Patients were
required to have an Eastern Cooperative Oncology Group
performance status of 2 or greater, no evidence of active
cardiac abnormalities, adequate bone marrow reserve,
serum total bilirubin 1.5 mg/dL, and a calculated or
measured creatinine clearance greater than 60 mL/min.
Patients were excluded if they had a history of malig-
nancy within the past 5 years (other than non-
melanomatous skin cancer or carcinoma-in-situ of the
cervix) or preexisting peripheral neuropathy greater than
grade I. When this study was initially designed, HPV
status was not routinely tested at our institution; however,
where possible, HPV status is also reported.
Treatment and evaluation
Induction chemotherapy and radiation
The treatment scheme is shown in Fig 1. All chemo-
therapy was calculated using actual body weight and
administered in the outpatient chemotherapy infusion
center. Following standard premedication (steroid, H1 and
H2 blockers, and physician choice of antiemetics), pacli-
taxel was diluted in 0.9% sodium chloride to a ﬁnal
concentration of 0.3 to 1.2 mg/mL and was given at a
dose of 75 mg/m2 intravenously over 1 hour on days 1, ,8
and 15 of a 21-day cycle. Following paclitaxel infusion on
day 1, carboplatin, reconstituted in 0.9% sodium chloride
to a ﬁnal concentration of approximately 10 mg/mL, was
given over 30 minutes at an area under the curve of 6,Figure 1 Schema describing the regimen of clinical trial
02-HN-15: low-dose fractionated radiation therapy þ carbo-
platin and paclitaxel. Solid bars represent 50 cGy fractions of
radiation. SCCHN, squamous cell cancer of the head and neck.calculated using the Calvert formula (day 1 only). Two
doses of 50 cGy radiation were given on days 1, 2, 8, and
15. The ﬁrst fraction was given within 1 hour of
completion of chemotherapy; the second fraction given 3
to 6 hours later with the third and fourth fractions given
on day 2 separated by at least 3 hours (Fig 1). Patients
were treated with shaped ﬁelds encompassing gross dis-
ease only (including the primary and gross nodal disease)
with a maximum 2-cm margin. The primary site was
treated with photons and lymph nodes with electrons,
with spinal cord was excluded from the radiation ﬁeld.
Three-dimensional treatment planning was used in all
patients. The total irradiation dose for induction therapy
(total of 2 cycles) was 800 cGy (50 cGy  8 fractions per
cycle).
Dose modiﬁcation
Chemotherapy dose modiﬁcations were required on
days 8 and 15 for any of the following: absolute neutro-
phil count <800/mL, platelet count <50,000/mL, greater
than grade 3 mucositis, grade 3 motor or sensory neu-
ropathy, grade 3 arthralgias or myalgias, grade 3 fatigue,
grade 2 or 3 hepatic dysfunction, or greater than grade 3
other nonhematologic toxicity. Patients were allowed a
maximum of 2 dose reductions according to the following
guidelines in Table 1.
Development of grade 4 sensory/motor neuropathy,
arthralgias/myalgias, and fatigue or liver dysfunction
required removal from protocol. Patients were required to
have an absolute neutrophil count >800/mL and platelets
>50,000/mL on day 22 to proceed with cycle 2 of therapy.
No dose reescalation was permitted and treatment delays
of longer than 2 weeks required removal from protocol.
Posttherapy evaluation
Radiographic tumor assessment by CT or magnetic
resonance imaging scan and panendoscopy or indirect
laryngoscopy, where appropriate, was performed within 4
weeks after the completion of the last dose or LDFRT.
Biopsy was performed if there was a question of disease
response. Response assessment used Response Evaluation
Criteria in Solid Tumors, version 1.0.31Nodal responsewas
assessed clinically and radiographically and was scored
separately from the primary tumor response with overall
response graded based on combined primary and nodalTable 1 Dose modiﬁcations
Modiﬁcation
episode
Carboplatin (area
under the curve)
Paclitaxel
(mg/m2)
0 6 75
-1 5 65
-2 4 55
Table 2 Patient characteristics (N Z 24 evaluable)
Variable N %
Gender
Male 22 91.7
Female 2 8.3
Age (y)
Median (range) 54 (38-66)
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Institute’s Common Toxicity Criteria, version 3.0.32
Deﬁnitive therapy
Deﬁnitive radiation began within 1 week after the
completion of 2 cycles of induction, with decisions
regarding therapy made by a multidisciplinary team.
Response at the primary site was used to determine the total
dose of deﬁnitive radiation: patients with CR to induction
were treated with reduced dose of radiation at the primary
site (reduced from 70 Gy to 60-66 Gy) and had 2 cycles of
intravenous cisplatin (100 mg/m2) instead of 3. Those with
partial response or stable disease (SD) were treated with
surgery and adjuvant therapy or with altered fractionation
regimens. In calculating the planned total dose of radiation
to be used for deﬁnitive therapy, the radiation oncologist
incorporated the induction dose used into the ﬁnal calcu-
lation for a maximum total dose (inductionþ deﬁnitive) of
approximately 7640 cGy (once-daily fractionation, 180
cGy/fraction) or 8320 cGy (twice-daily fractionation, 120
cGy/fraction). In all deﬁnitive radiation treatment plans,
either a 3- or 4-ﬁeld setup was used, 3-dimensional-based
treatment planning was used for all but 1 patient (who
required intensity modulated radiation therapy), electrons
were used to treat posterior neck nodes after spinal cord
block and the spinal cord was limited to 45 Gy.
P16 expression
Surgical pathology slides from pretreatment tumor
biopsies were collected for immunohistochemical evalu-
ation. At the time of initiation of this study, p16 staining
was not routinely performed; however, retrospectively
adequate tumor samples were analyzable for p16 status in
11 patients (45.83%). Staining methods have been
reported previously33 and a blinded independent pathol-
ogist reviewed and characterized the formalin-ﬁxed,
parafﬁn-embedded, immunostained sections. Tumors
were classiﬁed as positive when >75% showed diffuse
nuclear and cytoplasmic staining.34Primary tumor site
Oropharynx 15 62.5
Larynx 5 20.8
Oral cavity 2 8.3
Hypopharynx 2 8.3
Overall stage
III 7 29.2
IVa 13 54.2
IVb 4 16.7
Nodal stage
N0-N2a 12 50
N2b-N3 12 50
Tumor stage
T1, T2 13 54.2
T3, T4 11 45.8Statistical analysis
The primary endpoint for this study was pathologic
primary site CR rate, with secondary endpoints of nodal
response, overall RR, OS, PFS, disease-speciﬁc survival
(DSS), and toxicity. For statistical purposes, the historical
pathologic primary site CR to induction therapy for stage
II (bulky), III, and IV SCCHN patients was considered to
be 23% as documented in our previous experience with
LDFRT induction.30 We hypothesized improvement with
this regimen to at least 50%; therefore, 25 patients would
provide at least an 80% power to detect signiﬁcant dif-
ference between the pathologic primary site CR for theproposed regimen to the prior reference regimen,
assuming a 2-sided alpha level of 0.05.35
Primary site CR, nodal RR, and overall RR were
estimated with corresponding 95% conﬁdence intervals.
Descriptive statistics including medians/ranges for
continuous outcomes and frequency/percent for categori-
cal variables are presented for both baseline and
treatment-performance characteristics. Kaplan-Meier
curves were constructed for OS, DSS, and PFS with log
rank P values calculated to test for differences between
p16 staining. All data analyses were conducted using
SAS, version 9.3, for Windows (SAS Inc., Cary, NC).Results
Patient characteristics
From December 2002 to September 2004, 25 patients
with locally advanced SCCHN were enrolled and 1 was
lost to follow-up; baseline characteristics are listed in
Table 2. Median follow-up time of 93.08 months (range,
1.4-120 months) and primary sites included: oropharynx
(62.5%), larynx (20.8%), oral cavity (8.3%), and hypo-
pharynx (8.3%). All patients were chemotherapy naïve
and this was their ﬁrst diagnosis of SCCHN.
Acute and late toxicity
Grade 3 and 4 acute toxicities to induction therapy for all
patients enrolled (nZ25) included: neutropenia 6/25 (24%),
leukopenia 7/25(28%), dehydration and hypotension 2/25
Table 3 Grades I-IV acute toxicity for all patients enrolled
(N Z 25)
Toxicity NCI toxicity grade
I II III IV
N (%) N (%) N (%) N (%)
Leukopenia 5 (20) 7 (28) 5 (20) 2 (8)
Neutropenia 3 (12) 7 (28) 6 (24) -
Anemia 16 (64) 3 (12) 1 (4) -
Thrombocytopenia 10 (40) 1 (4) - -
Infection/fever 1 (4) 2 (8) 1 (4) -
Neutropenic - - - -
Nonneutropenic 1 (4) 2 (8) 1 (4) -
Arthralgias/myalgias 1 (4) 1 (4) - -
Nausea 5 (20) 1 (4) - -
Alopecia 15 (60) 10 (40) - -
Diarrhea 2 (8) 1 (4) 1 (4) -
Dyspepsia - 3 (12) - -
Constipation 1 (4) - - -
Hypotension/dehydration - 2 (8) 2 (8) -
Allergic rhinitis - 1 (4) - -
Neuropathy 5 (20) 1 (4) - -
Fatigue/weakness 2 (8) 2 (8) - -
Nephrolithiasis - 1 (4) - -
Dermatologic 1 (4) - - -
Pulmonary (dyspnea) - - 1 (4) -
Agitation - 1 (4) - -
Epistaxis 1 (4) - - -
NCI, National Cancer Institute.
Table 4 Response to LDFRT, carboplatin, and paclitaxel
at primary and nodal sites, presented as frequency (percent)
Response N CR PR SD PD RR
Primary site 24 15 (62.5) 8 (33.3) 1 (4.2) - 23 (95.8)
Nodal 19 9 (47.4) 7 (36.8) 3 (15.8) - 16 (84.2)
Overall 24 9 (37.5) 13 (54.2) 2 (8.3) - 22 (91.7)
Response rates at primary site, nodes, and overall. Note that only 19
patients had nodal disease.
CR, complete response; LDFRT, low-dose fractionated radiation
therapy; PD, progressive disease; PR, partial response; RR, response
rate; SD, stable disease.
Table 5 OS, PFS, and DSS survival estimates
OS PFS DSS
2 y 83.3 (69.7-99.7) 78.3 (63.1-97.1) 87.0 (74.2-100.0)
5 y 79.2 (64.5-97.2) 78.3 (63.1-97.1) 82.6 (68.5-99.6)
7 y 73.9 (57.8-94.5) 72.2 (55.3-94.3) 82.6 (68.5-99.6)
9 y 49.4 (30.5-79.9) 72.2 (47.8-86.7) 65.4 (44.3-96.4)
Median 107.2 (89.6-NA) Not yet reached Not yet reached
DSS, disease-speciﬁc survival; NA, not available; OS, overall sur-
vival; PFS, progression-free survival.
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(4%), pulmonary (dyspnea) 1/25 (4%), and diarrhea 1/25
(4%) (Table 3). No treatment-related deaths occurred. Late
toxicities of the cohort (n Z 24) included: 1/24 osteor-
adionecrosis, percutaneous gastrostomy tube dependence in
1/24, and lingual artery hemorrhage from local recurrence in
1/24. Induction therapy delays and dose reductions included
1 patient with a 1-week delay in therapy (during cycle 2) and
3 patients with dose reductions in the second cycle of
chemotherapy.
Response assessment to induction and P16INK4a
status
Primary site RR was 95.8% with 62.5% CR, 33.3%
PR, and 4.2% SD. Of the 19 patients with nodal disease,
nodal response was 84.2% (Table 4). Overall RR (primary
and nodal) was 91.7%. p16 expression was available in 11
patients, with RR occurring in 3/4 (75%) p16-negative
patients, 13/13 (100%) of p16 status unknown patients,
and 6/7 (85.7%) p16-positive patients.
Deﬁnitive therapy
Fifteen patients (65.2%) received concurrent chemo-
therapy and radiation: 2 hyperfractionated with intra-arterialcisplatin, 1 hyperfractionated with intravenous cisplatin,36
with 13 of these patients receiving once-daily fractionation
with intravenous cisplatin; 4 (16.7%) patients received
radiation alone, 1 patient had preoperative radiation and
surgery, and 4 patients (16.7%) had surgery. Radiation was
givenwithout treatment interruptions except in 1 patientwho
refused radiation after 4000 cGy.
OS and patient status
With a median follow-up of 93 months (7.75 years),
5-year OS was 79.2% and 9-year was 49.4%. Median OS
was 107.2 months with median PFS and DSS not yet
reached (Table 5, Fig 2). Although not statistically sig-
niﬁcant, median OS for p16-negative patients was 60.8
months, 107.2 months for p16 status unknown, and me-
dian not reached for p16-positive patients (P Z .0614;
eFigure 1; available as supplementary material online
only at www.practicalradonc.org).
Patient status
Fourteen patients (58.3%) remain alive and well, 4
(16.7%) died of other causes, and 6 (25%) have subse-
quently died of progressive disease with a median survival
time of 27.8 months (range, 15.2-107.2) following deﬁni-
tive therapy. Of those who have recurred, 1 larynx patient
had a previous CR to induction therapy, 3 (2 oropharynx, 1
larynx) had a PR, and 2 (1 oral cavity, 1 oropharynx)
showed SD during induction therapy. Patterns of recur-
rence included 2 locoregional, 3 distant, and 1 with
Figure 2 Overall (OS), progression-free, and disease-speciﬁc survival.
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nancies occurred as follows: prostate cancer (2), squamous
cell skin cancer (2), second SCCHN (1), third SCCHN (1),
non-small cell lung cancer, (2), small cell lung cancer (1),
and skin cancer not otherwise speciﬁed (1).Discussion
The use of LDFRTwith chemotherapy provides a novel
way to maximize tumor response, using radiation as a
“biologic” agent in combination with chemotherapy
(essentially, the third agent in this triplet combination). By
potentiating the effect of chemotherapy, low-dose radiation
targets area at highest risk (the tumor bed) and upregulates
the apoptotic proteins bax and bcl-x29,37 in the micro-
enviroment that will most beneﬁt from this upregulation. In
this setting, radiation has a very different purpose than its
traditional role in high-dose fractionation. Beyond very low
doses of radiation (>50 cGy), there is a relative increase in
the resistance to cell killing by radiation, termed induced
radiation resistance (IRR).33 The development of IRR is
dependent on intact DNA repair mechanisms25; the in-
duction of DNA repair pathways after DNA damage by
radiation may be the regulator of IRR. The HRS response is
independent of the DNA-dependent protein kinase com-
plex used to repair double-stranded DNA damage.25 This
suggests that the HRS phenomenon is not dependent on
DNA repair mechanisms25 and that the use of LDFRTmay
selectively favor pro-apoptotic pathways26; therefore, HRS
may provide a way to exploit radiation cell killing, without
inducing DNA repair, thus providing a way to avoid the
development of radiation resistance. Further exploration of
the mechanism is ongoing.34,35
Induction therapy is a reasonable component of
aggressive treatment of locally advanced SCCHN and was
an excellent clinical model to allow us to evaluate the effect
of low-dose radiation combined with chemotherapy. It iswell-recognized that induction does add additional toxicity
and triple-drug regimens increase the incidence of cytope-
nias and grade 5 toxicities. Using LDFRT as the third agent
in a multidrug chemotherapy induction scheme did not add
signiﬁcant toxicity to the traditional side effects of
chemotherapy. LDFRT potentiated the effect of induction
chemotherapy asmeasured by an overall RRof 91.7%. This
is the second report of the initial and long-term efﬁcacy of
induction therapy in SCCHN using a novel paradigm of
LDFRT (ultrafractionation) and chemotherapy.26,30,38-40
The use of radiation to potentiate the effect of chemo-
therapy, termed chemopotentiation, demonstrates long-
term survival in this high-risk, locally advanced cohort of
patients with SCCHN. Excellent primary site and overall
RR of 91.7% are predictive of excellent local control and a
5-yearOS of 79.2%and 9-yearOS of 49.4%; indicating that
this effect is durable in this population and has the potential
to be translated to other cancer sites that use chemotherapy
in the induction setting or as primary treatment. Our OS and
PFS are also equivalent or superior to the largest induction
regimens with long-term follow-up (TAX-234/235) with
improved overall survival compared with historical con-
trols (eTable 1). With regard to p16-positive patients, our
ﬁndingsmirror those of others; p16-positive oropharyngeal
and nonoropharyngeal subsets had better outcomes than
p16-negative cohorts.6
This combination of LDFRT, carboplatin, and paclitaxel
is well-tolerated, with toxicities comparable to carboplatin
and paclitaxel alone in a similar patient population.23,24 In
fact, there were no unexpected adverse events and no evi-
dence that LDFRT increased the rate of radiation-induced
grade 3/4 toxicities during induction therapy or long-term
complication rates: 1 patient each with osteoradionec-
rosis, long-term percutaneous gastrostomy tube depen-
dence, and arterial hemorrhage (resulting from cancer
progression). When compared with reported toxicity rates
of triplet therapy (docetaxel, cisplatin, and 5-ﬂuorouracil),
this study demonstrates reduced toxicity, chieﬂy in terms of
258 S.M. Arnold et al Advances in Radiation Oncology: OctobereDecember 2016neutropenia and mucositis.22,25 Deﬁnitive therapy did not
have to be delayed (in the case of radiation or surgery) or
interrupted (radiation) and did not affect the tolerability of
subsequent therapy.
The primary endpoint of improved primary site CR
was reached, with improvement from 28% in the ﬁrst trial
to 62.5% in this present study. The RRs of this trial are
comparable to trials using 2-drug and16,23,24 and 3-drug
regimens13,41 with less toxicity. The present study used
only 2 cycles of induction and achieved a RR of 91.7%
and enhanced the CR rate at the primary site from our
previous study by more than 2-fold30 as well as those of
other induction therapy studies using similar agents
(eTable 2). This improved control at the primary site
allowed for dose deescalation of deﬁnitive chemo-
radiation without loss of efﬁcacy, as previously reported
in studies by Urba and Haraf.17,42 Primary site CR rate
served as a reliable surrogate marker of sensitivity to
deﬁnitive radiation and is a signiﬁcant endpoint for in-
duction therapy studies. It is important with regard to
patient toxicity in head and neck cancer because it can
identify sensitive tumors that will respond to lower doses
of deﬁnitive radiation and chemotherapy.
When comparing the present clinical trial with other
neoadjuvant strategies that used 3- and 4-drug chemo-
therapy regimens,15,16,18,30,31 chemotherapy and LDFRT
provided similar results but less neutropenia (24% grade 3
and 4) and 24% grade 3 and 4 nonhematologic toxicity. In
a strategy criticized for increased toxicity, this induction
trial provides a 3-agent regimen, with no added toxicity.
Our ﬁndings are comparable to other reported out-
comes in nonsurgical approaches, with 5-year OS, PFS,
and DSS of 79.2, 78.3, and 82.6 months, respectively
(Table 5). Compared with large phase 3 trials, this is
favorable and shows the potential of chemopotentiating
LDFRT combined with paclitaxel and carboplatin. This
treatment paradigm, with an excellent 9-year OS of 49.4
months and median OS of 107.2 months, with median
PFS and DSS not yet been reached is notable, especially
coupled with the lower rate of grade 3 and 4 toxicities
compared with more intensive, 3-drug induction regi-
mens. This is the second innovative trial successfully
using LDFRT as a potentiator of chemotherapy. Many
other possibilities for harnessing the power of LDFRT
exist, including ultrafractionation alone, combination with
localized radiosensitizers, and combination with molecu-
larly targeted agents and immunotherapy. Further inves-
tigation of this concept in a randomized trial is ongoing.Acknowledgments
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